The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IWWM-12 2024 | Advancements in MRD testing for Waldenström’s macroglobulinemia: the ddPCR technique
Simone Ferrero, MD, University of Torino and Hospital “Città della Salute e della Scienza di Torino”, Torino, Italy, discusses the lack of data on measurable residual disease (MRD) testing in Waldenström’s macroglobulinemia (WM). He mentions a study using the highly sensitive droplet digital polymerase chain reaction (ddPCR) technique to track MRD in the peripheral blood in MYD88-mutated WM. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant: Janssen, EUSA Pharma, Abbvie and Sandoz; Advisory board: Janssen, EUSA Pharma, Recordati, Incyte, Roche, Astra Zeneca and Italfarmaco; Speaker’s honoraria: Janssen, EUSA Pharma, Recordati, Lilly, Beigene, Gilead and Gentili ; Research funding: Gilead, Beigene and Morphosys.
